AMPH Amphastar Pharmaceuticals Inc Stock Overview U.S.: Nasdaq

amph stock

On May 17, 2023, Amphastar Pharmaceuticals Inc (AMPH) had a median target price of $44.00, with a high estimate of $46.00 and a low estimate of $43.00, according to three analysts offering 12-month price forecasts. The current consensus among five investment analysts is to buy AMPH stock. The positive outlook for AMPH is likely due to the company’s strong financial performance in the current quarter, with earnings per share of $0.56 and sales of $136.8 million. Investors looking to capitalize on the positive outlook for AMPH may want to consider buying the stock before the company’s reporting date on August 09, 2023. However, it is important to note that investing in any stock carries inherent risks, and past performance does not guarantee future results.

Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.

How to buy AMPH stock on Public

The yield on the 10-year Treasury rose to 3.57% from 3.54% late Tuesday. Stocks of companies that get much of their revenue from the federal government, and thus may have much to lose if it can’t pay its bills, were ticking a bit higher. It’s also worth noting that AEHR is not solely reliant on the SiC market. While SiC will be its primary growth driver, it also announced a nice order – possibly from Intel (INTC) – in the silicon photonics integrated circuits market that will be shipped in its fiscal Q1. As I noted in my previous article, I don’t think a ~30x forward EBITDA multiple is out of line for valuing AEHR given its growth. Results were pretty much in line, while bookings were very strong, boding well for future growth.

Exact Sciences Earns Membership In 95-Plus Composite Rating Club – Investor’s Business Daily

Exact Sciences Earns Membership In 95-Plus Composite Rating Club.

Posted: Thu, 11 May 2023 07:00:00 GMT [source]

The day’s trading range was narrow, with the stock fluctuating between $42.40 and $42.47. The volume was relatively low, with only 29 shares traded compared to the average volume of 443,893 shares over the past three months. According to 4 analysts, the average rating for AMPH stock is “Buy.” The 12-month stock price forecast is $42.67, which is a decrease of -0.54% from the latest price.

Wall Street gains ground with hopes U.S. may avoid default

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. AMPH’s beta can be found in Trading Information at the top of this page.

He said targets of 76% occupancy by the end of this year and 78% by the end of 2024 are likely unachievable, which can lead to higher cash burn and prompt the need for outside capital. He also said the company will likely not be free cash flow positive until its 2025 fiscal year. WeWork shares dropped more than 17% after the company announced chairman and CEO Sandeep Mathrani would step down at the end of the month. We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.

amph stock

In recent news, Amphastar Pharmaceuticals has announced that Jacob Liawatidewi, Executive V.P. Of Corporate Administration Center, will be presenting at the Wells Fargo conference. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).

“The comes a moment in time when you hit the wall,” McCarthy said. “You can’t continue down this trajectory if you want to continue to be the strongest nation in the world.” To see more companies moving in the premarket, read the full story here.

Generic Drug Stocks to Watch Amid Macro Headwinds

Home prices in China fell, with prices 0.2% lower year-on-year, compared to a 0.8% decline seen in the previous month, according to Reuters’ calculations. “I think at the end of the day we do not have a debt default,” he said on CNBC’s “Squawk Box.” “I think we finally got the president to agree to negotiate.” In an exclusive interview with CNBC’s David Faber on the heels of the meeting Tuesday, CEO Elon Musk said he plans to spend more time on Tesla going forward, and devote a large chunk of time toward AI developments. Biden’s remarks underscore earlier comments from House Speaker Kevin McCarthy, who told CNBC in an interview that he doesn’t think the U.S. will default on its debt. Congressional leaders have been in tense negotiations with the White House over the approaching debt ceiling.

amph stock

Options trading entails significant risk and is not appropriate for all investors. Option investors can rapidly lose the value of their investment in a short period of time and incur permanent loss by expiration date. You need to complete an options trading application and get approval on eligible accounts. Please read the Characteristics and Risks of Standardized Options before trading options. Our clearing firm Apex Clearing Corp has purchased an additional insurance policy. The coverage limits provide protection for securities and cash up to an aggregate of $150 million, subject to maximum limits of $37.5 million for any one customer’s securities and $900,000 for any one customer’s cash.

The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. AEHR currently trades at an EV/EBITDA multiple of 37.6x the FY24 (ending May) consensus of $28.5 million. Based on FY25 EBITDA projections of $41.3 million, it trades at a 19x multiple.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Compare
AMPH’s historical performance
against its industry peers and the overall market. The two-year yield, which moves more on expectations for action by the Federal Reserve, rose to 4.15% from 4.08%. A day earlier, Home Depot raised worries when it cut its financial forecasts for the year after highlighting broad-based pressures across its business.

Treasury Secretary Janet Yellen has said that a default could come as early as June 1. “We had a productive meeting yesterday, and with all four leaders of the Congress – it was civil and respectful,” Biden said, speaking to the media. “And everyone came to the meeting, I think, in good faith. I’m confident that we’ll get the agreement on the budget, that America will not default.” The technician pointed out market activity on Monday as an example, when the most liquid short rose 3.68%, but then dropped 2.77% on Tuesday.

Most companies in the S&P 500 have turned in earnings that were better than analysts feared. But they’re still on pace to finish with a second straight quarter of drops in profit from year-ago levels. They’re staring down a June 1 deadline, which is when the U.S. government could default on its debt unless Congress allows it to borrow more. A default could rock the financial system because Treasurys are seen as the safest possible investment on Earth, and economists say it would likely cause widespread damage across the economy.

These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.

  • Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.
  • New product launches provide some respite to AMPH, RDY and SLGL.
  • They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.
  • That edged past analyst estimates calling for revenue of $17.0 million.
  • The Dow ended the trading session below a key threshold on Tuesday.

Get this delivered to your inbox, and more info about our products and services. MarketWatch’s daily roundup of stocks making significant moves in trading. Amphastar (AMPH) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. The impact of inflationary headwinds and pricing pressure on the Zacks Medical – Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL. The impact of macroeconomic headwinds on the Zacks Medical – Generic Drugs industry persists.

He is 58 years old, and he noted that his wife retired a few years ago. Looking ahead, the company said it was comfortable with its full-year guidance for revenue of between $60-70 million, which would be growth of 18-30%. It also continues to believe that bookings growth will be faster than revenue growth.

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *